Sign in
Taking people in United StatesPhase 1

Skipping radiation after surgery for brain metastasis, using cancer drugs that reach the brain

Tests leaving out radiosurgery after brain metastasis surgery, using systemic therapy instead.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
Status
Recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
27 May 2026
Expected to end
30 Jun 2030
Type of study
Interventional
Treatments tested
  • Systemic therapy
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had a brain metastasis from NSCLC (a lung cancer) or melanoma fully removed by surgery. They will skip radiation to the surgery site and take drug therapy that works in the brain instead.

Age
18 years or older
Sex
All sexes
Disease stage
A brain metastasis from NSCLC or melanoma, fully removed by surgery 5 weeks ago or less, with tissue tests confirming the cancer type. ECOG performance status of 2 or less (able to care for yourself). A brain tumor team must agree that radiation right after surgery can safely be skipped.
Earlier treatment
The removed tumor must never have had radiation. The cancer must not have grown during earlier treatment with the same drug type, and the last dose must be at least 6 months before the study drugs start. Planned study drugs: ipilimumab plus nivolumab for melanoma, osimertinib for EGFR-mutant NSCLC, or brigatinib, alectinib or lorlatinib for ALK-positive NSCLC.
Biomarker or test result
For NSCLC: an EGFR mutation (for example Exon 19 deletion or L858R) or an ALK rearrangement/fusion.

Main reasons for not taking part

  • Cancer known to have spread to the lining of the brain and spinal cord (leptomeningeal involvement)
  • Past or planned whole brain radiotherapy
  • Unacceptable side effects before from any of the planned study drugs
  • Unable to have a brain MRI or MRI contrast
  • Pregnancy or plans to become pregnant during the study

The registry criteria, word for word

Show all 18 criteriaShow less

Who cannot take part

  • Subjects that have previously received or are currently planned for whole brain radiotherapy
  • Prior unacceptable toxicity on one or more of the agents comprising the planned study systemic therapy
  • History of known leptomeningeal involvement (radiographic or cytological)
  • Cognitively impaired subjects with a major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled
  • Participant unable to receive a brain MRI (implanted metal devices or foreign bodies) or MRI contrast
  • Pregnancy or plans to become pregnant during the duration of the study

Other criteria

  • Eligibility Criteria
  • Age ≥ 18 years
  • ECOG performance status ≤ 2
  • Participants with a resected brain metastasis with gross total resection and pathologic confirmation of NSCLC or melanoma. Gross total resection must be confirmed based on a review of the operative report, pathology, and all post-operative images available at the time of enrollment
  • Brain metastasis resection occurred ≤ 5 weeks ago
  • Additional prior surgeries, including Laser Interstitial Thermal Therapy (LITT), to the same or nearby location are permitted, provided that residual disease or local recurrence is confirmed pathologically at the most recent resection
  • The resected lesion has never previously been targeted by radiotherapy
  • Evaluation by a brain metastasis multidisciplinary team (BM-MDT), consisting of a medical oncologist (can be the patient's primary medical oncologist), a radiation oncologist who regularly performs SRS, and a neurosurgeon, and agreement that the intracranial cavity does not or will not require immediate post-operative radiation (i.e. it is judged to be safe to omit post-operative radiation). This BM-MDT evaluation can take place in clinic or during a multidisciplinary conference, either before or after the surgical resection. If the BM-MDT evaluation was before the surgical resection, there can be no new findings in the interim (e.g. during or after the surgical resection) that would change the BM-MDT's recommendation, as determined by one or more of the patient's treating physicians
  • Documentation by the patient's primary medical oncologist of a planned study systemic therapy regimen consisting of one of the following: dual-agent immune checkpoint inhibitors (e.g. ipilimumab and nivolumab) for melanoma, osimertinib for EGFR Mutant (e.g. Exon 19 deletion; L858R) NSCLC, and brigatinib, alectinib, or lorlatinib for ALK rearranged/fusion positive NSCLC. As new agents are approved, other highly-CNS active tyrosine kinase inhibitors for participants with NSCLC may be included at the discretion of the principal investigator
  • For a participant with more than one recently resected brain metastasis that meets eligibility criteria #3-#7 above, it is permissible (but not mandated) for more than one surgical cavity to proceed without immediate post-operative radiation. All other intracranial disease must proceed with treatment according to standard-of-care practices at the time of enrollment. This may include treatment with SRS or observation if clinically appropriate
  • Regarding prior systemic therapy:; For participants with melanoma: no prior disease progression on any immune checkpoint inhibitor agent and ≥ 6 months between the last dose of any immune checkpoint inhibitor agent and initiation of the study systemic therapy regimen; For participants with EGFR Mutant NSCLC: no prior disease progression on any EGFR-targeted tyrosine kinase inhibitor and ≥ 6 month between the last dose of any EGFR-targeted tyrosine kinase inhibitor and initiation of the study systemic therapy regimen; For participants with ALK rearranged/fusion positive NSCLC: no prior disease progression on any ALK-targeted tyrosine kinase inhibitor and ≥ 6 month between the last dose of any ALK-targeted tyrosine kinase inhibitor and initiation of the study systemic therapy regimen
  • This study will allow non-English speaking subjects to be enrolled. Verbal Translation Preparative Sheet (VTPS) will be used if a translated consent form is not available in the subject's language. The consent form will be translated into the language of the subject after 2 or more occurrences. This will apply to any MD Anderson patient

This trial is currently available in United States.

  • MD Anderson Cancer CenterHouston, United StatesContact: Thomas H Beckham, MDTaking people

About the trial

What the trial wants to find out

To remove a brain tumor, patients usually receive radiation to lower the chance that the cancer will come back in the spot where the tumor was removed.

The group in the trial

  • systemic therapyTreatment being tested

    * Begin CNS active systemic therapy as recommended by your oncologist within 5 weeks after surgery. * Attend study visits every 12 weeks during Years 1 and 2. * Participate in 4 neurocognitive function assessments in specific windows of time. * Beyond 2 years, your medical records will continue to be reviewed to look at your health status, unless the participant withdraw or are withdrawn earlier.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
Plain-language title
Skipping radiation after surgery for brain metastasis, using cancer drugs that reach the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
15 September 2026